Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04398524

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx Clinical Trial

Official title:
A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy

Clinical Trial Summary

This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.

Clinical Trial Description

This study will assess the ability of ISA101b plus cemiplimab to improve Overall Response Rate in subjects who have progressed on prior anti-PD-1 therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04398524
Study type Interventional
Source ISA Pharmaceuticals
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 1, 2021
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Active, not recruiting NCT03669718 - A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC Phase 2
Withdrawn NCT01586182 - Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04151134 - Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Recruiting NCT05119036 - Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Phase 2
Recruiting NCT04031534 - Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma Phase 2
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Terminated NCT02552550 - Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Completed NCT01663259 - Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients N/A
Recruiting NCT04104945 - p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) N/A
Not yet recruiting NCT05962242 - HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT06061705 - Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies N/A
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT06112535 - Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery N/A
Completed NCT01921426 - A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Phase 1
Completed NCT01181648 - Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
Recruiting NCT05918510 - Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Recruiting NCT05894083 - A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) Phase 2